{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:40:24Z","timestamp":1789609224343,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.bbmt.2018.04.022","type":"journal-article","created":{"date-parts":[[2018,4,21]],"date-time":"2018-04-21T14:20:08Z","timestamp":1524320408000},"page":"1765-1770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"24","author":[{"given":"Alessandro","family":"Busca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Dellacasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0860-3266","authenticated-orcid":false,"given":"Luisa","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Manetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Biale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Godio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semra","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moreno","family":"Festuccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Brunello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.04.022_bib0010","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/00007890-198803000-00005","article-title":"Immunohematologic consequences of major ABO-mismatched bone marrow transplantation","volume":"45","author":"Sniecinski","year":"1988","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0015","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.V75.1.290.290","article-title":"Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation","volume":"75","author":"Gm\u00fcr","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1046\/j.1537-2995.2000.40050543.x","article-title":"Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems","volume":"40","author":"Worel","year":"2000","journal-title":"Transfusion"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0025","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/bjh.12210","article-title":"Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation","volume":"160","author":"Aung","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0030","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2141.2005.05364.x","article-title":"Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation","volume":"128","author":"Griffith","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0035","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.bbmt.2013.04.004","article-title":"Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors","volume":"19","author":"Hirokawa","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0040","first-page":"2216","article-title":"Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant","volume":"57","author":"Sackett","year":"2017","journal-title":"J Clin Apher"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0045","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-007-0304-8","article-title":"Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies","volume":"86","author":"Helbig","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0050","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00277-008-0599-0","article-title":"Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation","volume":"88","author":"Fang","year":"2009","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.bbmt.2018.04.022_bib0055","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/bmt.2011.176","article-title":"Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib","volume":"47","author":"Poon","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0060","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/sj.bmt.1705945","article-title":"Successful therapy of chronic graft-versus-host disease manifesting as pure red cell aplasia with single-agent rituximab","volume":"41","author":"Benson","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0065","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1600-0609.2004.00320.x","article-title":"Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion","volume":"73","author":"Verholen","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0070","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s002770000275","article-title":"Pure red cell aplasia after ABO-incompatible allogeneic stem cell transplantation in severe aplastic anemia with response to steroids: a case report and literature review","volume":"80","author":"Yang","year":"2001","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0075","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/tme.12143","article-title":"Pulsed-high-dose dexamethasone as a treatment for pure red cell aplasia following ABO-incompatible allogeneic stem cell transplantation","volume":"24","author":"Yang","year":"2014","journal-title":"Transfus Med"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0080","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/sj.bmt.1705378","article-title":"Response to high-dose dexamethasone for acquired pure red cell aplasia following ABO-mismatched allogeneic stem cell transplantation","volume":"37","author":"Deotare","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0085","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/tme.12121","article-title":"Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation","volume":"24","author":"Khan","year":"2014","journal-title":"Transfus Med"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0090","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1703668","article-title":"Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia","volume":"30","author":"Maschan","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0095","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/sj.bmt.1704264","article-title":"Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb immunoadsorption","volume":"32","author":"Rabitsch","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0100","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0105","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2012-04-425512","article-title":"Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study","volume":"121","author":"Saleh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1200931","article-title":"Eltrombopag and improved hematopoiesis in refractory aplastic anemia","volume":"367","author":"Olnes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0115","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","article-title":"Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug","volume":"123","author":"Desmond","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0120","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic anemia","volume":"376","author":"Townsley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0125","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.bbmt.2016.02.008","article-title":"Pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplantation is associated with severe pancytopenia","volume":"22","author":"Aung","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.scr.2012.05.001","article-title":"Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem\/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis","volume":"9","author":"Sun","year":"2012","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0135","first-page":"459","article-title":"Thrombopoietin has a differentiative effect on late-stage human erythropoiesis","volume":"105","author":"Liu","year":"1999","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.bbmt.2018.04.022_bib0140","first-page":"4","article-title":"Heterodimerization of TPO and IFN-\u03b3 impairs human hematopoietic stem\/progenitor cell signalling and survival in chronic inflammation, ASH Meeting","volume":"130","author":"Alvarado","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0145","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000204488","article-title":"Iron chelators may enhance erythropoiesis by increasing iron delivery to haematopoietic tissue and erythropoietin response in iron-loading anaemia","volume":"89","author":"Vreugdenhil","year":"1993","journal-title":"Acta Haematol"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0150","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1111\/j.1537-2995.2010.02617.x","article-title":"Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients","volume":"50","author":"Oliva","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0155","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3346\/jkms.2008.23.2.320","article-title":"Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis","volume":"23","author":"Park","year":"2008","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0160","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000158631","article-title":"Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis","volume":"120","author":"Messa","year":"2008","journal-title":"Acta Haematol"},{"key":"10.1016\/j.bbmt.2018.04.022_bib0165","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3324\/haematol.2011.048546","article-title":"Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes","volume":"97","author":"Gattermann","year":"2012","journal-title":"Haematologica"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118302258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118302258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:02:48Z","timestamp":1761058968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118302258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1083879118302258"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.04.022","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc. on behalf of the American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}